Half-year report · HY
4005.TEDINET S100X029
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.10T | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.61T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.24T | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥103.7bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥121.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥87.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥58.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥30.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥39.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥38.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥90.9bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.36T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.44T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.72T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.18T | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.37T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.18T | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.07T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.09T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥958.7bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥900.8bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥909.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥161.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥209.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥273.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥57.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥233.0bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥63.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥16.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥85.2bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥74.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥114.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥300.8bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥75.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥24.26 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.59 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-3.99 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥24.25 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Equity ratio | 28.5% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥47.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥22.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥24.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥36.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥36.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥16.2bn |
| Advanced Medical Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥27.5bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥21.1bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.4bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥1.4bn |
| Agro And Life Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥213.5bn |
| Agro And Life Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥213.0bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥504m |
| Agro And Life Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥11.2bn |
| Essential And Green Materialsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥331.6bn |
| Essential And Green Materialsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥329.1bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| Essential And Green Materialsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥18.6bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥284.9bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥283.5bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.5bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥33.1bn |
| Sumitomo Pharmareportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥227.1bn |
| Sumitomo Pharmareportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥226.1bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.1bn |
| Sumitomo Pharmareportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥97.3bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.08T |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.07T |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥11.8bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥121.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥85.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥50.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥34.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥19.4bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥45.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥45.1bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥16.3bn |
| Advanced Medical Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.8bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥26.8bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5.0bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥355m |
| Agro And Life Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥225.8bn |
| Agro And Life Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥225.0bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥830m |
| Agro And Life Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.2bn |
| Essential And Green Materialsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥453.8bn |
| Essential And Green Materialsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥450.9bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.8bn |
| Essential And Green Materialsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥34.8bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥309.5bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥307.5bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥43.6bn |
| Sumitomo Pharmareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥180.4bn |
| Sumitomo Pharmareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥180.4bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥47m |
| Sumitomo Pharmareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.20T |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.19T |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥10.7bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥26.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 916
| Item | Context | Value | Unit |
|---|---|---|---|
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | -34759000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00752-000SumitomoPharmaReportableSegmentMember | 3040000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_ReportableSegmentsMember | 26378000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 19412000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_ReconcilingItemsMember | -16314000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration | 29476000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 212971000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 283482000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | 21142000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | 329144000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00752-000SumitomoPharmaReportableSegmentMember | 226071000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReportableSegmentsMember | 1072810000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 22584000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | InterimDuration | 1095394000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 504000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 1453000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | 6391000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | 2432000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000SumitomoPharmaReportableSegmentMember | 1051000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReportableSegmentsMember | 11831000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 24772000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReconcilingItemsMember | -36603000000 | JPY |
| Intersegment revenue IFRS | InterimDuration | － | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 213475000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 284935000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | 27533000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | 331576000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00752-000SumitomoPharmaReportableSegmentMember | 227122000000 | JPY |
| Revenue IFRS | InterimDuration_ReportableSegmentsMember | 1084641000000 | JPY |
| Revenue IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 47356000000 | JPY |
| Revenue IFRS | InterimDuration_ReconcilingItemsMember | -36603000000 | JPY |
| Revenue IFRS | InterimDuration | 1095394000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AgroAndLifeSolutionsReportableSegmentMember | 11227000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00752-000ICTAndMobilitySolutionsReportableSegmentMember | 33109000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00752-000AdvancedMedicalSolutionsReportableSegmentMember | -1380000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00752-000EssentialAndGreenMaterialsReportableSegmentMember | -18610000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00752-000SumitomoPharmaReportableSegmentMember | 97320000000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReportableSegmentsMember | 121666000000 | JPY |
| Segment profit loss IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3235000000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReconcilingItemsMember | -16185000000 | JPY |
| Segment profit loss IFRS | InterimDuration | 108716000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-10 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第145期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)住友化学株式会社 | |
| Company name in english cover page | FilingDateInstant | SUMITOMO CHEMICAL COMPANY, LIMITED | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 水 戸 信 彰 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |